Back

Eloxx doses first two patients in Phase 2b Alport syndrome study

Verifying
  • Eloxx Pharmaceuticals dosed the first two patients in the Phase 2b EXACT Study.
  • The trial will evaluate exaluren in 24 patients with nonsense mutation Alport syndrome.
  • Topline data are expected in mid-2027, with a final readout due by end-2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.